Education
About Us
Working with TipRanks
Follow Us
Virpax Pharmaceuticals (VRPX)
OTHER OTC:VRPX
Total Valuation
Virpax Pharmaceuticals has a market cap or net worth of $298.20K. The enterprise value is $4.14M.
Market Cap$298.20K
Enterprise Value$4.14M
Share Statistics
Virpax Pharmaceuticals has 1,242,504 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding1,242,504
Owned by Insiders0.12%
Owned by Institutions0.09%
Financial Efficiency
Virpax Pharmaceuticals’s return on equity (ROE) is 13.21 and return on invested capital (ROIC) is 1322.00%.
Return on Equity (ROE)13.21
Return on Assets (ROA)-7.76
Return on Invested Capital (ROIC)1322.00%
Return on Capital Employed (ROCE)13.22
Revenue Per Employee0.00
Profits Per Employee-6.03B
Employee Count2
Asset Turnover0.00
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Virpax Pharmaceuticals is >-0.01. Virpax Pharmaceuticals’s PEG ratio is >-0.01.
PE Ratio>-0.01
PS Ratio0.00
PB Ratio>-0.01
Price to Fair Value>-0.01
Price to FCF>-0.01
Price to Operating Cash Flow>-0.01
PEG Ratio>-0.01
Income Statement
In the last 12 months, Virpax Pharmaceuticals had revenue of 0.00 and earned -12.07B in profits. Earnings per share was -2.84K.
Revenue0.00
Gross Profit0.00
Operating Income-12.08B
Pretax Income-12.07B
Net Income-12.07B
EBITDA-12.08B
Earnings Per Share (EPS)-2.84K
Cash Flow
In the last 12 months, operating cash flow was -16.71M and capital expenditures 0.00, giving a free cash flow of -16.71M billion.
Operating Cash Flow-16.71M
Free Cash Flow-16.71M
Free Cash Flow per Share-13.45
Dividends & Yields
Virpax Pharmaceuticals pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta1.61
52-Week Price Change-99.61%
50-Day Moving Average1.94
200-Day Moving Average12.06
Relative Strength Index (RSI)19.27
Average Volume (3m)192.08K
Important Dates
Virpax Pharmaceuticals upcoming earnings date is May 19, 2025, TBA Not Confirmed.
Last Earnings DateMar 26, 2025
Next Earnings DateMay 19, 2025
Ex-Dividend Date―
Financial Position
Virpax Pharmaceuticals as a current ratio of 0.63, with Debt / Equity ratio of 0.00%
Current Ratio0.63
Quick Ratio0.63
Debt to Market Cap0.00
Net Debt to EBITDA<0.01
Interest Coverage Ratio116.43
Taxes
In the past 12 months, Virpax Pharmaceuticals has paid 0.00 in taxes.
Income Tax0.00
Effective Tax Rate0.00
Enterprise Valuation
Virpax Pharmaceuticals EV to EBITDA ratio is >-0.01, with an EV/FCF ratio of >-0.01.
EV to Sales0.00
EV to EBITDA>-0.01
EV to Free Cash Flow>-0.01
EV to Operating Cash Flow>-0.01
Balance Sheet
Virpax Pharmaceuticals has $1.51M in cash and marketable securities with $0.00 in debt, giving a net cash position of -$1.51M billion.
Cash & Marketable Securities$1.51M
Total Debt$0.00
Net Cash-$1.51M
Net Cash Per Share-$1.22
Tangible Book Value Per Share-$214.78
Margins
Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.
Gross Margin0.00%
Operating Margin0.00%
Pretax Margin0.00%
Net Profit Margin0.00%
EBITDA Margin0.00%
EBIT Margin0.00%
Analyst Forecast
The average price target for Virpax Pharmaceuticals is ―, which is 11.43% higher than the current price. The consensus rating is Hold
Price Target―
Price Target Upside―
Analyst ConsensusHold
Analyst Count1
Revenue Growth Forecast―
EPS Growth Forecast60.26%